Susan Hasty, Publisher
Table of Contents . . . December 11th, 1995Non-Subscriber - Summaries Only
Non-Hodgkin's Lymphoma - Viral Agent Like HCV Involved in NHL
Cancer Gene Therapy - Bystander Effect of HSV-tk/GCV Mediated by Gap Junctions
Cancer Gene Therapy - Expression of bcl-xs Purges Cancer Contaminated Bone Marrow
Blood Banking (CMV) - Leukocyte-Reduction Is Effective As Screening for Preventing CMV
Brain Cancer - Nuclear Waste Pact Could Fund Cancer Center
Breast Cancer (Genetics) - Overzealous Gene May Play Early Role in Cancer
Cancer Vaccines - Researchers Use Dendritic Cells To Treat Experimental Cancers
Clinical Trials - Interleukin-2 Fusion Toxin Tested as Cancer Therapeutic
Graft-Versus-Host Disease (Therapy) - Thalidomide Is Confirmed Active in Treating Chronic GVHD
Industry News (Clinical Trials) - Lym-1 Enters Phase III of FDA Testing
Industry News (Diagnostics) - FDA Approves OncoScint CR/OV for Repeat Administration
Industry News (Diagnostics) - Trial of Cancer Blood Test Begins in Germany
Industry News (Immunology) - FLT3 Ligand Stimulates Growth of Dendritic Cells
Industry News (Patents and Technology) - Clinical Patent Developments Announced
Industry News (Therapy) - European Commission Approves Taxotere
Industry News (Transplantation) - Leukine Cleared for Use in Allogeneic BMT
Vector (Enhancement) - MoMLV Long Terminal Repeat Activation Enhances Retroviral Titer
Vectors (Design) - Integrin-Mediated Gene Delivery: The Good Things Add Up
Adjuvants (Gene Therapy) - "IL-12 Engineered Dendritic Cells Serve as Effective Vaccine Adjuvants In Vitro and In Vivo."
Cancer Gene Therapy (Animal Models) - "Preclinical Animal Models of Cancer Gene Therapy Using IL-12."
Combination Therapies - "The Application of IL-12 to Cytokine Therapy and Gene Therapy of Tumor."
Antisense Technology (Leukemia Therapy) - "Poor Cellular Uptake of Antisense Oligodeoxynucleotides: An Obstacle to Their Use in Chronic Myeloid Leukaemia."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.